Last updated 16 days ago
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
490 patients around the world
Available in Argentina, Chile, Mexico, United States, Brazil, Peru, Spain
Bristol-Myers Squibb
38Research sites
490Patients around the world
This study is for people with
Lupus
Systemic lupus erythematosus
Requirements for the patient
To 75 Years
All Gender
Medical requirements
Sites
Fundación Sanatorio Güemes - CABA, Buenos Aires
Recruiting
CER Instituto Médico - Quilmes, Buenos Aires
Recruiting
Centro Dermatológico Schejtman
Recruiting
Hospital Universitario Austral - Pilar
Recruiting
Hospital Italiano de La Plata
Recruiting
Hospital El Cruce - Nestor Kirchner
Recruiting
Centro de Investigaciones Médicas Tucumán
Recruiting
Centro Integral de Reumatología - Tucumán
Recruiting
Centro de Investigación Pergamino SA
Recruiting
Hospital Alemão Oswaldo Cruz
Recruiting
StudyPOETYK SLE-2
SponsorBristol-Myers Squibb
Study typeInterventional
Conditions
Systemic lupus erythematosus
Requirements
To 75 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05620407
